Gabapentin Tablet, Film Coated
Product Images NDC 70518-2616

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2616). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 600mg 70518 2616 01

Gabapentin 600mg 70518 2616 01
Gabapentin is a prescription drug with the NDC # 70518-2616-01. It is manufactured by Aurcbindo in Nagar, India 505302, and sourced by NDC 65862-0523-01. The lot number and expiration date are not available. It should be stored below 26°C (63-77°F) with excursions permittedto 15-30°C (59-86°F) and kept out of the reach of children. The package insert should be consulted for directions of use. It has been repackaged by RemedyRepack Inc., Indiana, PA 15701.*
FDA Label Image

Gabapentin 600mg 70518 2616 02

Gabapentin 600mg 70518 2616 02
Gabapentin is a prescription drug that comes in a package with the NDC number 70518-2616-02. The medicine is manufactured by Aurcbindo in Nagar, India. The LOT number and expiration date are missing from the text. The drug should be kept away from children and should be stored at 20-26°C (63-77°F), with permissible excursions allowed up to 15-30°C (59-86°F) as per USP guidelines. The packaging also refers to instructions enclosed in the package insert. RemedyRepack Inc., located in Indiana, Pennsylvania and with contact number 724.466.8762, has repackaged the drug.*
FDA Label Image

Gabapentin 600mg 70518 2616 03

Gabapentin 600mg 70518 2616 03
Gabapentin is a medication that is only available through prescription. It is packaged in a box with an NDC number and a LOT number. The medication is made by a manufacturer named Aurcbindo, located in Nagar, India. It is important to keep the medication out of reach of children. The directions for use can be found in the package insert. The medication should be stored at a temperature between 20-26°C, with permitted excursions between 15-30°C. It has been repackaged by RemedyRepack Inc. in Indiana, PA.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Gabapentin is a prescription-only medication manufactured by Aurcbindo in India. The NDC number is 70518-2616-00, and the source NDC is 65862-0523-01. The package insert should be consulted for directions for use. The medication should be stored at temperatures between 20-26°C (63-77°F) with excursions allowed to 15-30°C (59-86°F) [See USP]. The lot number and expiration date are not available. The medication should be kept out of reach of children. The drug has been repackaged by RemedyRepack Inc., Indiana, PA.*
FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

Creatinine Clearance (Gabapentin Fig1)
This appears to be a formula for calculating Lt, possibly related to the measurement of creatinine in female patients. However, without additional context or information, it is difficult to provide a more specific or useful description.*
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)
This text describes a figure labeled "Figure 1" that displays the weekly mean pain scores in an ITT population for a study. The figure includes different treatment groups, including a placebo group and a group taking gabapentin at 300mg/day. The text also displays some gibberish characters and is missing context to fully understand the study and its results.*
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)
This appears to be a table or chart showing the difference in figures between adjuvant therapy and placebo for a study on partial seizures in individuals aged 12 years old. The chart includes different doses of medication measured in milligrams over a period of time. Further information or context may be necessary to fully understand the purpose and findings of this data.*
FDA Label Image

Chemical Structure (Gabapentin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.